Penpulimab + Investigator's choice of Chemotherapy
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkin Disease Lymphoma
Conditions
Hodgkin Disease Lymphoma
Trial Timeline
Feb 15, 2022 → Mar 30, 2026
NCT ID
NCT05244642About Penpulimab + Investigator's choice of Chemotherapy
Penpulimab + Investigator's choice of Chemotherapy is a phase 3 stage product being developed by Akeso for Hodgkin Disease Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05244642. Target conditions include Hodgkin Disease Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05244642 | Phase 3 | Recruiting |
Competing Products
20 competing products in Hodgkin Disease Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Tirabrutinib | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| ONO-7018 + ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY4152199 - IV | Eli Lilly | Phase 1 | 33 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| enzastaurin + placebo | Eli Lilly | Phase 3 | 77 |